Bolt Biotherapeutics, Inc. Stock Price, News & Analysis

Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2022 financial results, highlighting $223.6 million in cash to fund operations through 2025. Clinical progress includes the ongoing BDC-1001 dosage studies, with anticipated data readouts later this year. The company has prioritized its pipeline, ceasing BDC-2034 due to off-target toxicity, while focusing on BDC-1001 and BDC-3042. Collaboration revenue rose to $1.4 million, a 75% increase from Q1 2022. R&D expenses fell slightly to $18.9 million, while G&A expenses rose to $5.5 million.

Bolt Biotherapeutics announces a presentation at the 2022 ASCO Annual Meeting in Chicago, showcasing data on myeloid cell presence in solid tumors, even with low T cell infiltration. The poster, titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)," highlights myeloid cells' potential as therapeutic targets. The insights could enhance the efficacy of myeloid-targeted therapies, benefiting patients resistant to T cell approaches. The abstract number is 2557, and the poster session is scheduled for June 5.

Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.

Bolt Biotherapeutics (BOLT) reported its financial results for Q4 and the full year 2021, showcasing a cash balance of $271.6 million to fund operations through 2024. The company is progressing with BDC-1001, a treatment for HER2-expressing solid tumors, expected to reach Phase 2 dose identification later in 2022. The ongoing combination study with OPDIVO® is advancing well, showing promising stability and partial responses. R&D expenses rose to $75.7 million, reflecting increased clinical trial costs. Total revenue for 2021 was $1.3 million, marking growth from $0.2 million in 2020.

Bolt Biotherapeutics (Nasdaq: BOLT) will present three preclinical pipeline programs at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The company is focused on immuno-oncology therapeutics combining antibody precision with immune system power. Key presentations include BDC-2034, targeting CEA, expected to enter clinical development in late 2022; BDC-3042, a Dectin-2 targeting antibody anticipated for 2023; and a PD-L1-targeting ISAC. Each program shows promise in anti-tumor activity and future clinical development.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology firm, recently announced upcoming presentations at two key conferences in February 2022. The first is the Guggenheim 2022 Oncology Virtual Conference on February 9 at 10:00 a.m. PT, followed by the SVB Leerink Global Healthcare Conference on February 16 at 2:00 p.m. PT. Both events will feature fireside chats, available for live streaming on Bolt's website, with archived replays accessible for 90 days post-event.

Bolt focuses on innovative immuno-oncology agents, particularly its lead candidate, BDC-1001, targeting HER2-expressing tumors.

Bolt Biotherapeutics (Nasdaq: BOLT) announced the first patient has been dosed in a new combination arm of its Phase 1/2 clinical trial for BDC-1001, which is being evaluated alongside Bristol Myers Squibb’s OPDIVO® (nivolumab). This trial targets HER2-expressing solid tumors. Preliminary findings from the single-agent portion showed a safe profile, supporting the promising potential of BDC-1001. Bristol Myers Squibb is providing OPDIVO for the trial, while Bolt is responsible for execution costs.

Bolt Biotherapeutics (Nasdaq: BOLT) has appointed Nicole Onetto, M.D., to its Board of Directors as of December 14, 2021. Dr. Onetto brings 30 years of oncology experience from various pharmaceutical and biotech companies. Her expertise in clinical development will be crucial as Bolt advances its immuno-oncology programs. Dr. Ashish Khanna is stepping down from the board after serving since July 2018. The company focuses on developing innovative immuno-oncology agents, particularly using its Boltbody™ ISAC approach to treat HER2-expressing solid tumors.